Sei Investments Co. Acquires 62,359 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Sei Investments Co. boosted its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 189.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 95,315 shares of the company’s stock after acquiring an additional 62,359 shares during the quarter. Sei Investments Co.’s holdings in PROCEPT BioRobotics were worth $7,675,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Raleigh Capital Management Inc. bought a new position in shares of PROCEPT BioRobotics in the 4th quarter worth $32,000. Signaturefd LLC grew its stake in PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock valued at $55,000 after purchasing an additional 145 shares during the last quarter. IFP Advisors Inc purchased a new stake in shares of PROCEPT BioRobotics during the fourth quarter valued at about $58,000. Arcadia Investment Management Corp MI bought a new stake in shares of PROCEPT BioRobotics in the 4th quarter valued at about $64,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of PROCEPT BioRobotics in the 3rd quarter worth approximately $64,000. Institutional investors own 89.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Morgan Stanley lowered their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Wells Fargo & Company reissued an “overweight” rating and issued a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Finally, Truist Financial restated a “buy” rating and set a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $94.29.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares of the company’s stock, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares in the company, valued at approximately $6,161,966.46. This represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is owned by insiders.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $60.05 on Monday. PROCEPT BioRobotics Co. has a 52 week low of $45.56 and a 52 week high of $103.81. The business’s 50 day moving average price is $65.34 and its 200 day moving average price is $77.82. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. The firm has a market cap of $3.29 billion, a P/E ratio of -30.79 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million during the quarter, compared to analysts’ expectations of $66.79 million. On average, sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).